Clinical Trials on Multiple Myeloma, Relapsed in Canada
Total 4009 results
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
AmgenActive, not recruitingRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid LeukemiaUnited States, Australia, Japan, Germany, Canada
-
Ciusss de L'Est de l'Île de MontréalUnknownRelapsed Multiple Myeloma | Relapsed Non Hodgkin Lymphoma | Hematologic Cancer | Relapsed Adult AML | Relapse Leukemia | Relapsed Adult ALL | Relapsed CLL | Relapsed Hodgkin's Lymphoma | Relapsed Myelodysplastic SyndromesCanada
-
University of ChicagoNational Cancer Institute (NCI)Active, not recruitingStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple MyelomaUnited States, Canada
-
AHS Cancer Control AlbertaTom Baker Cancer CentreRecruitingMyeloma | Myeloma MultipleCanada
-
GlaxoSmithKlineTerminatedRelapsed/Refractory Multiple MyelomaAustralia, Sweden, Canada
-
TakedaCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States, Canada
-
Washington University School of MedicineBristol-Myers Squibb; CelgeneActive, not recruitingMultiple Myeloma in RelapseUnited States, Canada
-
Canadian Myeloma Research GroupCompletedMultiple Myeloma in RelapseCanada
-
AmgenCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaCanada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
-
ORIC PharmaceuticalsRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Canada
-
Canadian Myeloma Research GroupGlaxoSmithKlineRecruitingRelapsed and/or Refractory Multiple MyelomaCanada
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaKorea, Republic of, Italy, Germany, France, Japan, Israel, Belgium, Denmark, Sweden, Canada, Spain, Czechia, Poland, Australia, Netherlands, United Kingdom, India, China
-
AmgenCompletedRelapsed Multiple MyelomaUnited States, Canada
-
AEterna ZentarisCompletedMultiple Myeloma and Plasma Cell NeoplasmCanada
-
ModernaTX, Inc.WithdrawnRelapsed or Refractory Multiple MyelomaUnited States, Canada
-
PETHEMA FoundationRecruitingMultiple Myeloma in RelapseSpain
-
TakedaTerminatedRelapsed and/or Refractory Multiple Myeloma (RRMM)United States, Canada
-
PETHEMA FoundationGlaxoSmithKlineRecruitingRELAPSED AND/OR REFRACTORY MULTIPLE MYELOMASpain
-
Hoffmann-La RocheRecruitingRelapsed or Refractory Multiple MyelomaKorea, Republic of, Denmark, Spain, Australia, Italy, New Zealand, France, Canada, Germany
-
Cleave Biosciences, Inc.TerminatedLymphoid Hematological Malignancies | Relapsed and Refractory Multiple MyelomaCanada, United States
-
AmgenCompletedRelapsed or Refractory Multiple MyelomaUnited States, Belgium, Australia, Spain, Canada, Netherlands
-
PETHEMA FoundationCompletedRelapsed and Refractory Multiple MyelomaSpain
-
AmgenTerminatedRelapsed/Refractory Multiple MyelomaUnited States, Australia, Japan, Germany, Netherlands, Canada
-
Regeneron PharmaceuticalsRecruiting
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaCanada
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States, Canada
-
University Health Network, TorontoMultiple Myeloma Research ConsortiumTerminatedMultiple Myeloma | Relapsed/RefractoryCanada
-
K36 Therapeutics, Inc.RecruitingMultiple Myeloma | Myeloma | Myeloma MultipleUnited States, France, Spain, Canada
-
BeiGeneRecruitingRelapsed/Refractory Multiple MyelomaUnited States, China, Australia, Korea, Republic of, Canada, United Kingdom, New Zealand, Brazil
-
AHS Cancer Control AlbertaAbbott; Tom Baker Cancer CentreCompleted
-
Ottawa Hospital Research InstituteRecruiting
-
Regeneron PharmaceuticalsRecruitingRelapsed Refractory Multiple Myeloma (RRMM)Canada, United States, Korea, Republic of, Israel, Spain, Australia, Brazil, United Kingdom, Poland, Taiwan, Singapore, France, Italy
-
AmgenCompletedRelapsed Multiple MyelomaUnited States, Canada, United Kingdom, France, Belgium, Austria, Spain, Israel, Italy, Bulgaria, Czechia, Germany, Greece, Hungary, Netherlands, Poland, Romania, Russian Federation, Serbia, Sweden
-
Novartis PharmaceuticalsCompletedRelapsed or Refractory Multiple MyelomaUnited States, Turkey, Canada, Netherlands, Australia, Germany, France
-
AbbVieGenentech, Inc.CompletedRelapsed/Refractory Multiple MyelomaUnited States, Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
-
Bristol-Myers SquibbRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
-
Millennium Pharmaceuticals, Inc.CompletedRelapsed and/or Refractory Multiple MyelomaUnited States, France, Norway, Spain, Israel, United Kingdom, Italy, Australia, Germany, Greece, Canada, Czechia, Turkey, Russian Federation, Denmark, Sweden, Belgium, Netherlands
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Canada, Australia, China, Germany, Belgium, Malaysia, Turkey, Japan, Israel, Sweden, Spain, United Kingdom, Czechia, Denmark, Brazil, Italy, France, Netherlands, Poland, Austria, Portugal, Greece, India
-
Ciusss de L'Est de l'Île de MontréalCelgene; C3i Center Inc.Active, not recruitingMultiple Myeloma | Relapsed Hematologic MalignancyCanada
-
University Health Network, TorontoTerminatedLymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Multiple Myeloma | Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | MyelodysplasiaCanada
-
CelgeneRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
-
SanofiActive, not recruitingPlasma Cell MyelomaItaly, Korea, Republic of, Norway, Canada, Spain, Germany, Greece, Lithuania, Sweden, Israel, Hungary, France, Japan, Australia, China, Denmark, Czechia, Turkey, United States, Brazil, Ireland, New Zealand, Poland, United Kingdom
-
NCIC Clinical Trials GroupCompletedMultiple Myeloma and Plasma Cell NeoplasmCanada
-
AmgenCompletedEnd-stage Renal Disease | Relapsed Multiple MyelomaUnited States, Australia, Canada
-
NCIC Clinical Trials GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompletedMultiple Myeloma and Plasma Cell NeoplasmCanada
-
London Health Sciences CentreCanadian Institutes of Health Research (CIHR); The Kidney Foundation of CanadaCompletedMultiple Myeloma | Acute Renal FailureCanada
-
Canadian Cancer Trials GroupCanadian Institutes of Health Research (CIHR); Myeloma CanadaRecruiting
-
University Health Network, TorontoAbbVie; CelgeneTerminatedAcute Myeloid Leukemia | Relapsed Cancer | Refractory Cancer | IDH2 Gene MutationCanada
-
Ciusss de L'Est de l'Île de MontréalExCellThera inc.; Centre C3iActive, not recruitingMultiple MyelomaCanada